GSK plc (NYSE:GSK) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.
GSK sales hampered by slump in demand for key vaccine
The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...
FiercePharma22d
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...
EuropaWire26d
GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps
(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...
Targeted Oncology28d
The Targeted Pulse: Uncover Essential Developments in Breast Cancer, Multiple Myeloma, and NSCLC Treatment and the Latest FDA Approvals
Belantamab mafodotin-blmf (Blenrep), combined with pomalidomide (Pomalyst) and dexamethasone (BPd), demonstrated a higher percentage of patients achieving meaningful improvements compared with ...
Business Insider29d
Assessing Genmab’s Financial Outlook Amidst Darzalex Market Challenges and Patent Expiry Concerns
Werber acknowledges the mounting pressure from GSK’s Blenrep, which is expected to re-launch and present strong Phase 3 data, potentially disrupting Darzalex’s market dominance. The ...